Skip to content
lifestyle.dietfitnessforall.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nanoscope Therapeutics
/C O R R E C T I O N — Nanoscope Therapeutics/
October 1, 2026
Nanoscope Therapeutics Announces PMDA Acceptance and Priority Review of New Drug Application for MOGENRY® in Japan for the Treatment of Inherited Retinal Dystrophies
October 1, 2026
Nanoscope Therapeutics to Present at Meeting on the Mesa 2026
September 29, 2026
Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum
September 23, 2026
Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting
September 15, 2026
Nanoscope Therapeutics to Participate in the 28th Annual H.C. Wainwright Global Investment Conference
September 11, 2026
Nanoscope Therapeutics Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for MOGENRY for the Treatment of Retinitis Pigmentosa with Severe Vision Loss
September 9, 2026
Nanoscope Therapeutics to Present Advanced Clinical and Manufacturing Findings at ASGCT 2026 Annual Meeting
May 11, 2026
Nanoscope Therapeutics Announces Participation at Eyecelerator® and ARVO 2026 Annual Meetings
April 23, 2026